{"doi":"10.1002/ejhf.2083","title":"Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <scp>DAPA‐HF</scp>","abstract":"AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under-prescription of beta-blockers. Consequently, additional effective therapies are especially relevant in patients with COPD. The aim of this study was to examine outcomes related to COPD in a post hoc analysis of the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial. METHODS AND RESULTS: We examined whether the effects of dapagliflozin in DAPA-HF were modified by COPD status. The primary outcome was the composite of an episode of worsening HF or cardiovascular death. Overall, 585 (12.3%) of the 4744 patients randomized had a history of COPD. Patients with COPD were more likely to be older men with a history of smoking, worse renal function, and higher baseline N-terminal pro B-type natriuretic peptide, and less likely to be treated with a beta-blocker or mineralocorticoid receptor antagonist. The incidence of the primary outcome was higher in patients with COPD than in those without [18.9 (95% confidence interval 16.0-22.2) vs. 13.0 (12.1-14.0) per 100 person-years; hazard ratio (HR) for COPD vs. no COPD 1.44 (1.21-1.72); P < 0.001]. The effect of dapagliflozin, compared with placebo, on the primary outcome, was consistent in patients with [HR 0.67 (95% confidence interval 0.48-0.93)] and without COPD [0.76 (0.65-0.87); interaction P-value 0.47]. CONCLUSIONS: In DAPA-HF, one in eight patients with HFrEF had concomitant COPD. Participants with COPD had a higher risk of the primary outcome. The benefit of dapagliflozin on all pre-specified outcomes was consistent in patients with and without COPD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03036124.","journal":"European Journal of Heart Failure","year":2020,"id":62989,"datarank":1.654556026504158,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"self_citation_contribution":0.5837730447165941,"citation_network_contribution":1.0707829817875638,"self_endowment_contribution":0.5837730447165941,"citer_contribution":1.0707829817875638,"corpus_percentile":null,"corpus_rank":null,"citation_count":48,"citer_count":39,"citers_with_citation_signal":30,"citers_with_endowment":30,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9607,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03036124"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":57279,"name":"Kieran F. Docherty","orcid":"0000-0002-5446-9969","position":1,"is_corresponding":false},{"id":57281,"name":"Olof Bengtsson","orcid":"0000-0003-1315-8176","position":2,"is_corresponding":false},{"id":55735,"name":"Rudolf A. de Boer","orcid":"0000-0002-4775-9140","position":3,"is_corresponding":false},{"id":57261,"name":"Akshay S. Desai","orcid":"0000-0002-1443-0701","position":4,"is_corresponding":false},{"id":57289,"name":"Jarosław Dróżdż","orcid":"0000-0002-0732-2104","position":5,"is_corresponding":false},{"id":333431,"name":"Nathaniel M. Hawkins","orcid":"0000-0003-1286-2014","position":6,"is_corresponding":false},{"id":57254,"name":"Silvio E. Inzucchi","orcid":"0000-0003-1254-6636","position":7,"is_corresponding":false},{"id":57268,"name":"Masafumi Kitakaze","orcid":"0000-0001-5157-4213","position":8,"is_corresponding":false},{"id":2621,"name":"Lars Køber","orcid":"0000-0002-6635-1466","position":9,"is_corresponding":false},{"id":335381,"name":"M N Kosiborod","orcid":null,"position":10,"is_corresponding":false},{"id":226404,"name":"Anna Maria Langkilde","orcid":"0000-0002-1696-9356","position":11,"is_corresponding":false},{"id":262168,"name":"Daniel Lindholm","orcid":"0000-0003-3526-0614","position":12,"is_corresponding":false},{"id":57285,"name":"Felipe A. Martínez","orcid":"0000-0002-5836-972X","position":13,"is_corresponding":false},{"id":2664,"name":"Béla Merkely","orcid":"0000-0001-6514-0723","position":14,"is_corresponding":false},{"id":57272,"name":"Mark C. Petrie","orcid":"0000-0002-6333-9496","position":15,"is_corresponding":false},{"id":2670,"name":"Piotr Ponikowski","orcid":"0000-0002-3391-7064","position":16,"is_corresponding":false},{"id":50019,"name":"Marc S. Sabatine","orcid":"0000-0002-0691-3359","position":17,"is_corresponding":false},{"id":57274,"name":"Morten Schou","orcid":"0000-0002-1274-5072","position":18,"is_corresponding":false},{"id":57282,"name":"Mikaela Sjöstrand","orcid":"0000-0001-6253-9886","position":19,"is_corresponding":false},{"id":27970,"name":"Scott D. Solomon","orcid":"0000-0003-3698-9597","position":20,"is_corresponding":false},{"id":57276,"name":"Subodh Verma","orcid":"0000-0002-4018-8533","position":21,"is_corresponding":false},{"id":57280,"name":"Pardeep S. Jhund","orcid":"0000-0003-4306-5317","position":22,"is_corresponding":false},{"id":2612,"name":"John J.V. McMurray","orcid":"0000-0002-6317-3975","position":23,"is_corresponding":false},{"id":262167,"name":"Pooja Dewan","orcid":"0000-0003-2927-4075","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-18T21:11:00.632961Z","pmid":"33368858","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}